natgillin/translations-raw huggingface dataset:
Colourless Type I glass vials of 5 ml, 10 ml and 20 ml closed with a coated bromobutyl rubber stopper and aluminium cap in a carton box.
5-, 10- in 20-mililitrske viale iz brezbarvnega stekla tipa I, zaprte s prevlečenim gumijastim zamaškom iz bromobutilne gume in aluminijasto zaporko, v kartonski škatli.
1 or 5 vials of 10 ml
1 viala ali 5 vial z 10 ml
Sodium chloride
deksmedetomidinijev klorid
The expected sedative and analgesic effects are reached within 15 minutes after administration and are maintained up to 60 minutes after administration.
Pričakovani sedativni in analgetični učinki se pojavijo v 15 minutah po dajanju.
In cases of overdose, or if the effects of dexmedetomidine become potentially life- threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area).
Psi: V primeru prevelikega odmerjanja, ali če postanejo učinki deksmedetomidina potencialno nevarni za življenje, je treba uporabiti odmerek atipamezola, ki je 10-krat večji od prvotnega odmerka deksmedetomidina (v mikrogramih/kg telesne mase ali mikrogramih/kvadratni meter telesne površine).
The corresponding doses based on body weight are presented in the following tables.
Preglednica spodaj prikazuje ustrezne odmerke na podlagi telesne mase.
The dose for cats is 40 micrograms dexmedetomidine hydrochloride/kg bw equal to a dose volume of 0.08 ml Cepedex/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Odmerek za mačke je 40 mikrogramov deksmedetomidinijevega klorida/kg telesne mase, kar ustreza prostorninskemu odmerku 0,08 ml zdravila Cepedex/kg telesne mase pri uporabi za neinvazivne, blago do zmerno boleče postopke in preglede mačk, pri katerih so potrebni mirovanje, sedacija in analgezija.
The dose volume of atipamezole at the concentration of 5 mg/ml equals the dose volume of Cepedex 0.5 mg/ml that was given to the dog, regardless of route of administration of Cepedex.
Volumen odmerka atipamezola pri koncentraciji 5 mg/ml ustreza volumnu odmerka zdravila Cepedex 0,5 mg/ml, ki je bil dan psu, ne glede na način dajanja zdravila Cepedex.
The dose for cats is 40 micrograms dexmedetomidine hydrochloride/kg bw equal to a dose volume of 0.4 ml Cepedex/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Odmerek za mačke je 40 mikrogramov deksmedetomidinijevega klorida/kg telesne mase, kar ustreza prostorninskemu odmerku 0,4 ml zdravila Cepedex/kg telesne mase pri uporabi za neinvazivne, blago do zmerno boleče postopke in preglede mačk, pri katerih so potrebni mirovanje, sedacija in analgezija.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTS OR WASTE MATERIALS, IF ANY
ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI ALI ODPADNIH SNOVI, ČE
In cases of overdose, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate antagonist is atipamezole, administered by intramuscular injection, at the following dose: 5 times the initial dose of dexmedetomidine in micrograms/kg bw.
Mačke: V primeru prevelikega odmerjanja, ali če postanejo učinki deksmedetomidina potencialno nevarni za življenje, je treba uporabiti atipamezol v obliki intramuskularne injekcije v naslednjem odmerku: 5-kratni prvotni odmerek deksmedetomidina v mikrogramih/kg telesne mase.
The veterinary medicinal product is intended for:
Načeto zdravilo uporabite do:
For higher weight ranges, use Cepedex 0.5 mg/ml and its dosing tables.
Za večje razpone telesne teže uporabite zdravilo Cepedex 0,5 mg/ml in pripadajoče odmerne preglednice.
A prolonged elimination half-life is therefore expected with overdoses or when dexmedetomidine is coadministered with other substances, which affect hepatic circulation.
V primeru prevelikih odmerkov ali pri uporabi deksmedetomidina z drugimi snovmi, ki vplivajo na jetrni krvni obtok, lahko pričakujemo podaljšan razpolovni čas izločanja.
Reduced heart rate and temporary AV-block can be seen after administration of dexmedetomidine.
Po uporabi deksmedetomidina lahko opazimo upočasnjeno delovanje srca in začasni AV-blok.
Cepedex 0.1 mg/ml injection dexmedetomidine hydrochloride
Cepedex 0,1 mg/ml injekcija deksmedetomidinijev klorid
Cepedex 0.5 mg/ml solution for injection for dogs and cats dexmedetomidine hydrochloride
Cepedex 0,5 mg/ml raztopina za injiciranje za pse in mačke deksmedetomidinijev klorid
Cepedex 0.1 mg/ml solution for injection for dogs and cats dexmedetomidine hydrochloride
Cepedex 0,1 mg/ml raztopina za injiciranje za pse in mačke deksmedetomidinijev klorid
The safety of dexmedetomidine has not been established in males intended for breeding.
Pri samcih za razplod varnost deksmedetomidina ni bila dokazana.
When dexmedetomidine is used as a premedicant in dogs bradypnoea, tachypnoea and vomiting may occur.
Pri uporabi deksmedetomidina za premedikacijo psov lahko pride do bradipneje, tahipneje in bruhanja.
The dose volume of atipamezole at the concentration of 5 mg/ml is one-half the volume of Cepedex 0.5 mg/ml that was given to the cat.
Volumen odmerka atipamezola pri koncentraciji 5 mg/ml ustreza polovici volumna zdravila Cepedex 0,5 mg/ml, ki je bil dan mački.
Propyl parahydroxybenzoate
2,0 mg propilparahidroksibenzoat
This veterinary medicinal product does not require any special storage conditions.
Za shranjevanje ni posebnih navodil.
Cepedex 0.5 mg/ml injection dexmedetomidine hydrochloride
Cepedex 0,5 mg/ml injekcija deksmedetomidinijev klorid
The dose volume of atipamezole at the concentration of 5 mg/ml is one-half (1/2) the volume of Cepedex 0.5 mg/ml that was given to the cat.
Volumen odmerka atipamezola pri koncentraciji 5 mg/ml ustreza eni polovici (1/2) volumna zdravila Cepedex 0,5 mg/ml, ki je bil dan mački.
The dose volume of atipamezole at the concentration of 5 mg/ml is one-tenth (1/10) the volume of Cepedex 0.1 mg/ml that was given to the cat.
Volumen odmerka atipamezola pri koncentraciji 5 mg/ml ustreza eni desetini (1/10) volumna zdravila Cepedex 0,1 mg/ml, ki je bil dan mački.
Equipment for manual ventilation should be available in case of respiratory depression or apnoea when dexmedetomidine and ketamine are used sequentially to induce anaesthesia in cats.
Pri zaporedni uporabi deksmedetomidina in ketamina za anestezijo pri mačkah lahko pride do dihalnega zastoja ali prenehanja dihanja, zato imejte pri roki opremo za ročno ventilacijo.
Cepedex 0.5 mg/ml solution for injection for dogs and cats
Cepedex 0,5 mg/ml raztopina za injiciranje za pse in mačke
Cepedex 0.1 mg/ml solution for injection for dogs and cats.
Cepedex 0,1 mg/ml raztopina za injiciranje za pse in mačke.
Dexmedetomidine also induces a number of other α2-adrenoceptor mediated effects, which include piloerection, depression of motor and secretory functions of the gastrointestinal tract, diuresis and hyperglycaemia.
Mednje spadajo piloerekcija, upadanje motoričnih in sekretornih funkcij prebavil, diureza in hiperglikemija.
Cepedex 0.1 mg/ml solution for injection for dogs and cats
Cepedex 0,1 mg/ml raztopina za injiciranje za pse in mačke
After concurrent exposure to an overdose of dexmedetomidine (3 times the recommended dose) and 15 mg ketamine/ kg, atipamezole can be administered at the recommended dose level for reversal of effects induced by dexmedetomidine.
15 mg ketamina/kg se lahko da atipamezol v priporočenem odmerku za izničenje učinkov deksmedetomidina.
In a clinical study, the requirement for propofol and thiopental was reduced by 30% and 60% respectively.
30 %, po tiopentalu pa za 60 %.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Deksmedetomidin je sedativ in uspavalo.
(equivalent to dexmedetomidine
(ki ustreza 0, 42 mg deksmedetomidina)
Corneal opacities may occur during sedation.
Med sedacijo lahko pride do motnosti roženice.
Intramuscularly: up to 500 micrograms/square metre body surface area.
(v mikrogramih/kg telesne mase ali mikrogramih/kvadratni meter telesne površine).
Take a tablet as soon as you remember and then continue as before.
Vzemite tableto takoj, ko se spomnite, in potem nadaljujte enako kot prej.
4.8 Undesirable effects a. Summary of the safety profile
4.8 Neželeni učinki a) Povzetek varnostnega profila
The highest overdose has been approximately 1.5 grams.
Največji preveliki odmerek je bil približno 1,5 grama.
Do not take a double dose to make up for a forgotten tablet dose.
Ne vzemite dvojnega odmerka, da bi nadoknadili pozabljeni odmerek.
These changes do not affect concentrations of free hormones.
Te spremembe pa ne vplivajo na koncentracije prostih hormonov.
Due to the nature of this disease process, Optruma is intended for long term use.
Zaradi narave tega bolezenskega procesa je zdravilo Optruma namenjeno dolgotrajni uporabi.
The women were 2 to 8 years postmenopausal.
Ženske so bile v menopavzi 2 do 8 let.
Raloxifene is strongly bound to plasma proteins (98-99 %).
Raloksifen se močno veže na plazemske beljakovine (98-99 %).
No other metabolites have been detected.
Našli niso nobenih drugih metabolitov.
• Flu syndrome
• Sindrom gripe
The volume of distribution is not dose dependent.
Njegov volumen porazdelitve ni odvisen od odmerka.
The majority of adverse reactions have not usually required cessation of therapy.
Večina neželenih učinkov običajno ni zahtevala prekinitve terapije.
• Increased blood pressure
• Zvišan krvni tlak
Each tablet contains lactose (149.40 mg).
Ena tableta vsebuje laktozo (149,40 mg).
de la Industria 30, 28108 Alcobendas (Madrid), Spain.
de la Industria 30, 28108 Alcobendas (Madrid), Španija.
This adverse reaction was most common in the first 6 months of treatment, and seldom occurred de novo after that time.
Ta neželeni učinek je bil najpogostejši v prvih 6 mesecih zdravljenja in se je kasneje le redko pojavil prvič.
Mechanism of action and Pharmacodynamic effect
Mehanizem delovanja in farmakodinamični učinki
This increase was generally a 2 % increase in BMD compared to placebo.
Na splošno je šlo za 2-odstotno povečanje BMD v primerjavi s placebom.
Your doctor will tell you how long you should continue to take Optruma.
Vaš zdravnik vam bo povedal, kako dolgo naj bi jemali zdravilo Optruma.
- The other ingredients are:
- Pomožne snovi so:
The Cmax of digoxin increased by less than 5 %.
Cmax digoksina se je povečala za manj kot 5 %.
A similar increase in BMD was seen in the treatment population who received Optruma for up to 7 years.
Podobno povečanje BMD so ugotovili pri zdravljeni populaciji, ki je prejemala zdravilo Optruma do 7 let.
The doctor may also advise you to take calcium and vitamin D supplements.
Morda vam bo tudi svetoval, da jemljite dodatke kalcija in vitamina D.
Renal insufficiency - Less than 6 % of the total dose is eliminated in urine.
Ledvična insuficienca - Manj kot 6 % celotnega odmerka se izloči z urinom.
• If you have had a cerebrovascular accident (e.g. stroke), or if your doctor has told you that you are at high risk of having one.
• Če ste že imeli cerebrovaskularni dogodek (npr. kap) ali če vam je vaš zdravnik povedal, da imate visoko tveganje za tak dogodek.
There is no evidence of endometrial proliferation.
Ni nobenih dokazov o proliferaciji endometrija.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na lokalno predstavništvo imetnika dovoljenja za promet z zdravilom:
One further change was seen which was not statistically significant (p > 0.05), but which did show a significant dose trend.
Opažena je bila še ena sprememba, katere pojavnost ni bila statistično značilna (p > 0,05), bila pa je v precejšnji meri odvisna od odmerka zdravila.
Approximately 60 % of an oral dose is absorbed.
Absorbira se približno 60 % peroralnega odmerka.
Date of first authorisation: 5 August 1998 Date of latest renewal: 11 August 2008
Datum zadnjega podaljšanja dovoljenja za promet: 11. avgust 2008
e) Effects on cognitive function
e) Vplivi na kognitivno funkcijo
In some clinical trials, daily doses were given up to 600 mg for 8 weeks and 120 mg, for 3 years.
V nekaterih kliničnih študijah so dajali dnevne odmerke do 600 mg v času 8 tednov in 120 mg v času 3 let.
You should talk to your doctor first.
Predhodno se posvetujte s svojim zdravnikom.
They are packed in blisters or in plastic bottles.
Pakirane so v pretisnih omotih ali plastičnih stekleničkah.
In accidental overdose in children younger than 2 years of age, the maximum reported dose has been 180 mg.
V naključnem prevelikem odmerjanju pri otrocih, mlajših od 2 let, so poročali o maksimalnem odmerku 180 mg.
• If you are receiving oral oestrogen therapy.
• Če prejemate peroralno estrogensko terapijo.
The bottles contain 100 tablets.
Stekleničke vsebujejo po 100 tablet.
This must be investigated by your doctor.
V tem primeru vas mora pregledati vaš zdravnik.
(listed in section 6).
(glejte poglavje 5.1).
Pharmacotherapeutic group: Selective Oestrogen Receptor Modulator, ATC code: G03XC01.
Farmakoterapevtska skupina: selektivni modulatorji estrogenskega receptorja, oznaka ATC: G03XC01.
If this medicinal product is used mistakenly during pregnancy or the patient becomes pregnant while taking it, the patient should be informed of the potential hazard to the foetus (see section 5.3).
Če ženska to zdravilo pomotoma vzame med nosečnostjo ali če bolnica zanosi med jemanjem tega zdravila, jo je treba obvestiti o možni nevarnosti za plod (glejte poglavje 5.3).
What Optruma is and what it is used for
Kaj je zdravilo Optruma in za kaj ga uporabljamo
Optruma may affect the development of the baby.
Zdravilo Optruma lahko vpliva na dojenčkov razvoj.
During the whole length of the study concomitant use of other bone-active medications was permitted.
Med celotnim trajanjem študije je bila dovoljena sočasna uporaba drugih zdravil, ki učinkujejo na kosti.
Optruma tablets are packed either in PVC/PE/PCTFE blisters or in high density polyethylene bottles.
Tablete Optruma so pakirane v pretisne omote PVC/PE/PCTFE ali v stekleničke iz polietilena visoke gostote.
What you need to know before you take Optruma Do not take Optruma:
Kaj morate vedeti, preden boste vzeli zdravilo Ne jemljite zdravila Optruma:
• If you have severe kidney problems.
• Če imate hude težave z ledvicami.
After 3 years therapy Optruma decreased fibrinogen (6.71 %).
Po 3 letih terapije z zdravilom Optruma je znižana vrednost fibrinogena (6,71 %).
The reproductive and developmental effects observed in animals are consistent with the known pharmacological profile of raloxifene.
Reproduktivni in razvojni učinki, ki so jih opažali pri živalih, so v skladu z znanim farmakološkim profilom raloksifena.
Discontinuation should happen as soon as possible in case of the illness, or from 3 days before the immobilisation occurs.
V primeru take bolezni je treba terapijo ustaviti, kolikor hitro je mogoče oz. 3 dni pred začetkom obdobja imobilizacije.
In the osteoporosis treatment trial, endometrial thickness was evaluated annually in a subset of the study population (1,644 patients) for 4 years.
V raziskavi zdravljenja osteoporoze so v obdobju vseh 4 let enkrat na leto ugotavljali debelino endometrija v podskupini opazovane populacije (1.644 bolnic).
Optruma are white, oval, film coated tablets which are marked with the number 4165.
Optruma so bele, ovalne, filmsko obložene tablete, ki so označene s številko 4165.
The risk of a thromboembolic event was greatest in the first four months of therapy.
Tveganje za pojav tromboemboličnih zapletov je bilo največje v prvih štirih mesecih terapije.
No adverse effects on cognitive function have been seen.
Opazili niso nobenih neželenih učinkov na kognitivno funkcijo.
• If there is still a possibility that you can get pregnant, Optruma could harm your unborn child.
• Če je še vedno možnost, da lahko zanosite, saj zdravilo Optruma lahko poškoduje vašega nerojenega otroka.
No fatalities associated with overdose have been reported.
O smrtnih primerih, povezanih s prevelikim odmerjanjem, niso poročali.
The blister boxes contain 14, 28 or 84 tablets.
Škatle s pretisnimi omoti vsebujejo po 14, 28 ali 84 tablet.
Any uterine bleeding during Optruma therapy is unexpected and should be fully investigated by a specialist.
Vsakršna krvavitev iz maternice med terapijo z zdravilom Optruma je nepričakovana in jo mora v celoti raziskati specialist.
Rare cases of moderate increases in AST and/or ALT have been reported where a causal relationship to raloxifene can not be excluded.
Poročali so tudi o redkih primerih zmernega zvišanja AST in/ali ALT, v katerih ni bilo mogoče izključiti vzročne povezave z raloksifenom.
The majority of a dose of raloxifene and glucuronide metabolites are excreted within 5 days and are found primarily in the faeces, with less than 6 % excreted in urine.
Izločanje Večji del odmerka raloksifena in njegovih glukuronidnih presnovkov se izloči v roku 5 dni in jih najdemo predvsem v blatu, manj kot 6 % pa se jih izloči z urinom.
Effects on prothrombin time may develop over several weeks if Optruma treatment is started in patients who are already on coumarin anticoagulant therapy.
Vplivi na protrombinski čas se lahko pokažejo šele čez nekaj tednov, če zdravljenje z zdravilom Optruma uvedemo pri bolnicah, ki so že na kumarinski antikoagulantni terapiji.
• Swelling of hands, feet and legs (peripheral oedema)
• Otekanje dlani, stopal in nog (periferni edem)
Optruma should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.
Zdravila Optruma ne bi smeli uporabljati pri bolnicah, ki kažejo znake ali imajo simptome raka endometrija, saj varnost zdravila pri tej skupini bolnic še ni bila zadosti raziskana.
Endometrial biopsies taken after six months therapy with Optruma 60 mg daily demonstrated nonproliferative endometrium in all patients.
Biopsija endometrija po šestih mesecih terapije z zdravilom Optruma v odmerku 60 mg na dan je pri vseh bolnicah pokazala neproliferativni endometrij.
Severe renal impairment.
Huda ledvična okvara.
Other medicines and Optruma
Druga zdravila in zdravilo Optruma
Elliptically shaped, white tablets imprinted with the code '4165'.
Eliptično oblikovane tablete bele barve, na katerih je odtisnjena šifra '4165'.
Increasing doses of raloxifene result in slightly less than proportional increase in the area under the plasma time concentration curve (AUC).
Povečevanje odmerkov raloksifena povzroči nekaj manj kot sorazmerno povečanje površine pod krivuljo plazemske koncentracije po času (AUC).
HDL cholesterol and triglyceride concentrations did not change significantly.
Koncentracije HDL holesterola in trigliceridov se niso značilno spremenile.
Teratology studies were conducted in rabbits and rats.
Raziskave teratogenih učinkov so opravili na kuncih in podganah.
Optruma was associated with reduced bone resorption and a mean positive shift in calcium balance of 60 mg per day, due primarily to decreased urinary calcium losses.
Uporaba zdravila Optruma je bila povezana z zmanjšano resorpcijo kostnega tkiva in s srednjim pozitivnim premikom ravnotežja kalcija za 60 mg na dan, kar je bilo predvsem posledica zmanjšane izgube kalcija z urinom.
Optruma is for use only by postmenopausal women and must not be taken by women who could still have a baby.
Zdravilo Optruma je namenjeno le ženskam po menopavzi in je ne smejo jemati ženske, ki bi še lahko zanosile.
In general, it does not change triglycerides or HDL ("good") cholesterol.
Na splošno ne vpliva na trigliceride ali HDL ('dobri') holesterol.
Nearly 3,000 transvaginal ultrasound (TVUs) examinations were evaluated from 831 women in all dose groups.
Proučili so rezultate skoraj 3.000 transvaginalnih ultrazvočnih preiskav pri 831 ženskah iz vseh skupin odmerjanja.
d) Effects on breast tissue
d) Vplivi na tkivo dojk
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA): http://www.ema.europa.eu
Optruma could harm your unborn child.
Zdravilo Optruma lahko poškoduje vašega nerojenega otroka.
This leaflet was last revised in month YYYY.
Navodilo je bilo nazadnje revidirano dne {mesec/LLLL}
• Skin around the vein is red and painful (superficial vein thrombophlebitis)
• Koža okrog ven je rdeča in boleča (tromboflebitis povrhnjih ven)
However, if you have taken oestrogen in the past and had extreme elevations in triglycerides, you should talk to your doctor before taking Optruma.
Če ste v preteklosti že jemali estrogene in ob tem imeli močno zvišane vrednosti trigliceridov, se pred jemanjem zdravila Optruma pogovorite s svojim zdravnikom.
No data are available on the concomitant use of Optruma and agents used in the treatment of early or advanced breast cancer.
Tako ni podatkov o sočasnem zdravljenju z zdravilom Optruma in drugimi zdravili, ki se uporabljajo za zdravljenje zgodnjega ali napredovalega raka dojke.
ii) Bone Mineral Density (BMD): The efficacy of Optruma once daily in postmenopausal women aged up to 60 years and with or without a uterus was established over a two-year treatment period.
ii) Mineralna kostna gostota (BMD): Učinkovitost zdravljenja z zdravilom Optruma enkrat dnevno so ugotavljali pri ženskah po menopavzi, starih do 60 let, z maternico ali brez nje, in sicer med 2-letnim zdravljenjem s tem zdravilom.
BOTTLE LABEL, BOTTLE CARTON:
OZNAKA NA STEKLENIČKI, ŠKATLA STEKLENIČKE:
These results may have been confounded by baseline differences in BMD and vertebral fractures.
Ti rezultati so morda bili presenetljivi glede na osnovne razlike v BMD in zlome vretenc.
If you have been told by your doctor that you have an intolerance to lactose, a type of sugar, contact your doctor before taking this medicinal product.
Če vam je zdravnik povedal, da ne prenašate laktoze, ki je vrsta sladkorja, se pred uporabo tega zdravila posvetujte s svojim zdravilom.
3 years.
do 60 mesecev.
After 4 years, raloxifene did not increase the risk of endometrial or ovarian cancer.
Po 4 letih raloksifen ni povečal tveganja za nastanek raka endometrija ali raka jajčnikov.
Optruma has no effect on the risk of ER negative breast cancers.
Zdravilo Optruma ne vpliva na tveganje za ER negativne vrste raka dojke.
Three trials included 1,764 postmenopausal women who were treated with Optruma and calcium or calcium supplemented placebo.
V treh kliničnih preskušanjih je sodelovalo 1.764 žensk po menopavzi, ki so bile zdravljene z zdravilom Optruma in dodatki kalcija ali s placebom in dodatki kalcija.
The increase correlated with total bilirubin concentrations.
Povečanje je bilo v korelaciji s koncentracijami celokupnega bilirubina.
• Blood clot in an artery (for example stroke, including an increased risk of dying from stroke)
• Krvni strdek v arteriji (na primer kap), vključno s povečanim tveganjem za smrt zaradi kapi
• Decrease in the number of the platelets in the blood
• Zmanjšanje števila krvnih ploščic v krvi
Absolute bioavailability of raloxifene is 2 %.
Njegova absolutna biološka uporabnost je 2 %.
Replacement therapies generally reverse the excessive resorption of bone.
Nadomestne terapije na splošno zavrejo prekomerno resorpcijo kostnega tkiva.
For oral use Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo!
Not all pack sizes may be marketed in all countries.
V vseh državah na trgu morda ni vseh navedenih pakiranj.
In addition, in a study with 2.5 x the recommended daily dose of Optruma there was no evidence of endometrial proliferation and no increase in uterine volume.
Poleg tega v raziskavi z 2,5-kratnim priporočenim dnevnim odmerkom zdravila Optruma ni bilo nobenih znakov proliferacije endometrija in niso ugotovili povečanja prostornine maternice.
Elderly: No dose adjustment is necessary for the elderly.
Pri starejših ni potrebna prilagoditev odmerkov.